|
|
Jazz Pharmaceuticals Plc (JAZZ) |
|
|
|
Jazz Pharmaceuticals Plc's Yearly Free Cash Flow Growth 5 Years |
|
Select the Comparisons :
|
|
Select the Ratio:
|
Annual Free Cash Flow Annual Growth Rates Y/Y▼
|
Annual Free Cash Flow Annual Growth Rates Y/Y▼
|
JAZZ Annual Free Cash Flow Growth |
2023
|
2022
|
2021
|
2020
|
2019
|
Y / Y Annual Free Cash Flow Change |
-12.31 % |
66.16 % |
-6.73 % |
17.3 % |
-6.34 % |
Annual Free Cash Flow (in millions $) |
$1,068.05 |
$1,217.93 |
$732.98 |
$785.90 |
$669.98 |
Annual Free Cash Flow Growth
Comment |
Jazz Pharmaceuticals Plc experienced detoriation of Annual Free Cash Flow for the fiscal year ended 2023 by -12.31% to $ 1,068.05 millions, compare to $ 1,217.93 in Annual Free Cash Flow reported in the previous year. The decline in company's annual Free Cash Flow accelerated, from the 66.16 % gain, in the fiscal year ended 2022.
Jazz Pharmaceuticals Plc Annual Income Statement
|
You need to upgrade your Flash Player
|
Companies with similar 2023 Annual Free Cash Flow within Healthcare Sector | Y/Y Free Cash Flow Growth % | 2023 Annual Free Cash Flow | Pfizer Inc | -81.59 % | $ 4,793.000 millions | Biontech Se | -61.34 % | $ 5,736.640 millions | Amgen Inc | -16.23 % | $ 7,359.000 millions | Gilead Sciences Inc | -11.06 % | $ 7,421.000 millions | Abbott Laboratories | -35.17 % | $ 5,059.000 millions | Medtronic Plc | -23.39 % | $ 4,580.000 millions | Eli Lilly And Company | -54.17 % | $ 2,396.800 millions | Regeneron Pharmaceuticals Inc | -12.42 % | $ 3,875.400 millions | 3m Company | 28.25 % | $ 5,184.000 millions | Vertex Pharmaceuticals Inc | -16.47 % | $ 3,278.900 millions | Viatris Inc | -4.84 % | $ 2,436.600 millions | Fresenius Medical Care Ag | 20.03 % | $ 2,962.332 millions | Royalty Pharma Plc | 39.36 % | $ 2,987.802 millions | Stryker Corp | 54.03 % | $ 3,136.000 millions | Becton Dickinson And Company | 41.26 % | $ 2,116.000 millions | Incyte Corporation | -49.67 % | $ 449.001 millions | Koninklijke Philips Nv | -5.84 % | $ 487.200 millions | Henry Schein Inc | -30.24 % | $ 353.000 millions | The Cooper Companies Inc | -52.26 % | $ 215.000 millions | West Pharmaceutical Services Inc | -5.67 % | $ 414.500 millions | Arcus Biosciences Inc | | | |